{"id":"NCT04175834","sponsor":"Providence Health & Services","briefTitle":"Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab","officialTitle":"Comparing the Risk and Severity of Infusion-Related Reactions in Patients Premedicated With Cetirizine Versus Diphenhydramine Prior to Ocrelizumab Infusions","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-05","primaryCompletion":"2022-05-13","completion":"2022-05-13","firstPosted":"2019-11-25","resultsPosted":"2024-03-04","lastUpdate":"2024-03-04"},"enrollment":19,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis","Infusion Reaction"],"interventions":[{"type":"DRUG","name":"cetrizine","otherNames":["Active comparator"]},{"type":"DRUG","name":"diphenhydramine","otherNames":["Other"]}],"arms":[{"label":"diphenhydramine","type":"OTHER"},{"label":"cetirizine","type":"ACTIVE_COMPARATOR"}],"summary":"This 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in Infusion-Related Reactions (IRRs) in subjects receiving ocrelizumab(OCR) for multiple sclerosis (MS).","primaryOutcome":{"measure":"Proportion of Participants With Infusion-related Reaction (IRR) on Day 0","timeFrame":"During or after the first-half dose of the first infusion on day 0","effectByArm":[{"arm":"Diphenhydramine","deltaMin":5,"sd":null},{"arm":"Cetirizine","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["28002679","28002688"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Infusion-related reaction","Infusion-related reaction","Infusion-related reaction"]}}